Classifying Transcutaneous Electrical Nerve Stimulator for Congestion Relief
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The FDA has classified a new device, the transcutaneous electrical nerve stimulator for congestion relief, into class II. This will mean less regulatory burdens for manufacturers while providing safety and effectiveness assurances. This decision affects medical device makers who will follow specific performance and safety guidelines for this type of device.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Device classified into class II to ensure safety and effectiveness
- Introduction of special controls for the device
- Reduced regulatory burdens for manufacturers
Obligations
What this law requires
Manufacturers of transcutaneous electrical nerve stimulators for congestion relief must submit a premarket notification under section 510(k) of the FD&C Act to reasonably assure the safety and effectiveness of the device.
Manufacturers of transcutaneous electrical nerve stimulators for the relief of congestion must demonstrate that the device performs as intended under anticipated conditions of use through non-clinical performance testing.
Manufacturers of transcutaneous electrical nerve stimulators for congestion relief must submit a premarket notification under section 510(k) of the FD&C Act unless exempted in the future.
Manufacturers must provide performance data demonstrating the electromagnetic compatibility, battery safety, and electrical safety of the device.
Manufacturers must demonstrate non-clinical performance testing that shows the device performs as intended under anticipated conditions of use.